Correlation Between Mesa Royalty and Interpace Biosciences

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Mesa Royalty and Interpace Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mesa Royalty and Interpace Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Mesa Royalty Trust and Interpace Biosciences, you can compare the effects of market volatilities on Mesa Royalty and Interpace Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mesa Royalty with a short position of Interpace Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mesa Royalty and Interpace Biosciences.

Diversification Opportunities for Mesa Royalty and Interpace Biosciences

  Correlation Coefficient

Good diversification

The 3 months correlation between Mesa Royalty and Interpace is -0.16. Overlapping area represents the amount of risk that can be diversified away by holding Mesa Royalty Trust and Interpace Biosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Interpace Biosciences and Mesa Royalty is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mesa Royalty Trust are associated (or correlated) with Interpace Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Interpace Biosciences has no effect on the direction of Mesa Royalty i.e., Mesa Royalty and Interpace Biosciences go up and down completely randomly.

Pair Corralation between Mesa Royalty and Interpace Biosciences

Considering the 90-day investment horizon Mesa Royalty Trust is expected to generate 0.73 times more return on investment than Interpace Biosciences. However, Mesa Royalty Trust is 1.38 times less risky than Interpace Biosciences. It trades about 0.09 of its potential returns per unit of risk. Interpace Biosciences is currently generating about -0.03 per unit of risk. If you would invest  332.00  in Mesa Royalty Trust on September 4, 2022 and sell it today you would earn a total of  1,446  from holding Mesa Royalty Trust or generate 435.54% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
ValuesDaily Returns

Mesa Royalty Trust  vs.  Interpace Biosciences

 Performance (%) 
Mesa Royalty Trust 
Mesa Royalty Performance
6 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in Mesa Royalty Trust are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Mesa Royalty reported solid returns over the last few months and may actually be approaching a breakup point.

Mesa Royalty Price Channel

Interpace Biosciences 
Interpace Performance
0 of 100
Over the last 90 days Interpace Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2023. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Interpace Price Channel

Mesa Royalty and Interpace Biosciences Volatility Contrast

   Predicted Return Density   

Pair Trading with Mesa Royalty and Interpace Biosciences

The main advantage of trading using opposite Mesa Royalty and Interpace Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mesa Royalty position performs unexpectedly, Interpace Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Interpace Biosciences will offset losses from the drop in Interpace Biosciences' long position.
Mesa Royalty vs. Amplify Energy Corp
Mesa Royalty vs. ATP Oil Gas
Mesa Royalty vs. Chesapeake Granite Wash
Mesa Royalty vs. Civitas Resources
The idea behind Mesa Royalty Trust and Interpace Biosciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Interpace Biosciences vs. Agilent Technologies
Interpace Biosciences vs. Etsy Inc
Interpace Biosciences vs. VANGUARD SMALL-CAP GROWTH
Check out your portfolio center. Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Probability Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Other Complementary Tools

Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Equity Valuation
Check real value of public entities based on technical and fundamental data
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years